News - Boehringer Ingelheim

Filter

Current filters:

Boehringer Ingelheim

Popular Filters

151 to 175 of 184 results

Flood of new cancer drug data presented at ASCO; nearly 1,000 being tested

04-06-2012

The annual prestigious American Society of Clinical Oncology (ASCO) meeting taking place in Chicago,…

afatinibBiotechnologyBoehringer IngelheimGenentechJanssenJohnson & JohnsonOncologyPharmaceuticalResearchRochetrastuzumab emtansineZytiga

EMA unit backs approval of Jentadueto; Agency updates on Pradaxa

28-05-2012

Independent German drug major Boehringer Ingelheim and US partner Eli Lilly (NYSE: LLY) have received…

Boehringer IngelheimCardio-vascularDiabetesEli LillyEuropeJentaduetoPharmaceuticalPradaxaRegulation

UK academia-pharma collaboration attracts £14.4 million funding

13-05-2012

In the UK, the University of Dundee and the Medical Research Council (MRC) have announced new funding…

AstraZenecaBoehringer IngelheimEuropeFinancialGlaxoSmithKlineJohnson & JohnsonMerck SeronoPfizerPharmaceuticalResearch

Breckenridge in generic Viramune deal with Zhejiang Huahai Pharma

07-05-2012

Privately-held US generic drugmaker Breckenridge Pharmaceutical that it has finalized its agreement with…

Anti-viralsAsia-PacificBoehringer IngelheimBreckenridge PharmaceuticalsGenericsMarkets & MarketingNevirapineNorth AmericaPatentsViramuneZhejiang Huahai Pharma

Boehringer Ingelheim says it is on growth path, as 2011 sales rise 6.2%

25-04-2012

German family-owned drug major Boehringer Ingelheim yesterday announced its financial results for full-year…

Boehringer IngelheimFinancialPharmaceutical

Promethera raises 23.6 million euros, with backers including Shire and Boehringer

28-03-2012

Belgian cell therapy company Promethera Biosciences yesterday completed a fundraising round that generated…

BiotechnologyBoehringer IngelheimFinancialHepaStemNephrology and HepatologyPromethera BiosciencesRegulationShire

Ablynx extends Nanobody deal with Boehringer

21-03-2012

Belgian drug developer Ablynx (Euronext Brussels: ABLX) yesterday announced a two-year extension of the…

AblynxBiotechnologyBoehringer IngelheimImmunologicalsLicensingOncologyPharmaceuticalRespiratory and Pulmonary

Caelyx and Ceplene manufacturing should be moved, says EMA

18-03-2012

The European Medicines Agency has recommended that the manufacturing processes for the anticancer medicines…

Boehringer IngelheimCaelyxCepleneEpiCeptJanssen-CilagJohnson & JohnsonOncologyPharmaceuticalRegulationRespiratory and Pulmonary

NICE recommends NHS use of Pradaxa

15-03-2012

In final guidance published today (March 15), the UK drug watchdog the National Institute of Health and…

Boehringer IngelheimCardio-vascularEuropePharmaceuticalPradaxaPricingRegulation

Boehringer Ingelheim links with Xencor on MAb supply

23-02-2012

Independent German drug major Boehringer Ingelheim has entered into a collaboration agreement with USA-based,…

BiotechnologyBoehringer IngelheimLicensingPharmaceuticalXencor

FDA approves combo diabetes drug Jentadueto and Kalydeco

01-02-2012

The US Food and Drug Administration) has approved Jentadueto (linagliptin/metformin hydrochloride) tablets,…

Boehringer IngelheimDiabetesEli LillyJentaduetoKalydecolinagliptinNorth AmericaPharmaceuticalRare diseasesRegulationVertex

Added benefit of Trajenta not proven, says German agency

10-01-2012

In an early benefit assessment under Germany’s "Act on the Reform of the Market for Medicinal Products”…

Boehringer IngelheimDiabetesEli LillyEuropePharmaceuticalRegulationTrajenta

FORMA Thera in up to $815 million deal with Boehringer

06-01-2012

Fast-growing US drug discovery firm FORMA Therapeutics has entered into an R&D collaboration with family-owned…

Boehringer IngelheimFORMA TherapeuticsOncologyPharmaceuticalResearch

UK ABPI gears up for next pricing negotiations; Boehringer breaches code

19-12-2011

The Associations of the British Pharmaceutical Association (ABPI) last Friday brought together pharmaceutical…

Boehringer IngelheimEuropeMarkets & MarketingPharmaceuticalPradaxaPricing

COPD market to grow to more than $13.4 billion in 2020

19-12-2011

As a result of an expanding aging population, increases in drug treatment and the uptake of premium priced…

Boehringer IngelheimGlobalMarkets & MarketingolodaterolPharmaceuticalRespiratory and Pulmonarytiotropium

Boehringer expands in China; Lundbeckfond ups ALK-Abello stake

15-12-2011

Family-owned German drug major Boehringer Ingelheim says it intends to invest 70 million euros ($91 million)…

Alk-AbelloAsia-PacificBoehringer IngelheimEuropeFinancialLundbeckfondPharmaceutical

FDA reviews Pradaxa bleeding risk

08-12-2011

Post-marketing reports of serious bleeding events in patients taking Pradaxa (dabigatran etexilate mesylate),…

Boehringer IngelheimCardio-vascularNorth AmericaPharmaceuticalPradaxaRegulation

EMA makes interim recommendations to deal with shortcomings at Ben Venue Labs

23-11-2011

The European Medicines Agency (EMA) is currently reviewing shortcomings in quality assurance identified…

Boehringer IngelheimEuropeMarkets & MarketingNorth AmericaPharmaceuticalRegulation

EMA says bleeding risks associated with Boehringer Ingelheim’s Pradaxa can be managed

20-11-2011

The European Medicines Agency on Friday providing an update on the safety of independent German drug…

Boehringer IngelheimCardio-vascularEuropePharmaceuticalPradaxaRegulation

Boehringer Ingelheim invests over $350 million in 2011 US expansion projects

17-11-2011

Privately-held German drug major Boehringer Ingelheim says that it has made more than $350 million worth…

Boehringer IngelheimFinancialNorth AmericaPharmaceuticalResearch

UK NICE recommends Boehringer’s Pradaxa for stroke prevention

01-11-2011

In final draft guidance published today (November 1), the UK’s drug watchdog the National Institute…

Boehringer IngelheimCardio-vascularEuropePharmaceuticalPradaxaPricingRegulation

Benefits of Boehringer’s Pradaxa come at high cost, study finds

20-10-2011

Treating patients with the new blood thinning medication dabigatran (German independent drug major Boehringer…

Boehringer IngelheimCardio-vascularNorth AmericaPharmaceuticalPradaxaPricing

Boehringer Ingelheim’s Combivent Respimat Inhalation Spray OKed in USA to replace aerosol

09-10-2011

The US Food and Drug Administration has approved German independent drug major Boehringer Ingelheim’s…

Boehringer IngelheimCombiventNorth AmericaPharmaceuticalRegulationRespiratory and Pulmonary

Boehringer license novel HIV non-catalytic integrase inhibitors to Gilead

07-10-2011

Two of the big names in HIV/AIDS drug research and marketing, the USA’s Gilead Sciences (Nasdaq:…

Anti-viralsBoehringer IngelheimGilead SciencesLicensingPharmaceutical

151 to 175 of 184 results

Back to top